Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

NCT01561456 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small-cell Lung Cancer
Squamous Cell Carcinoma
Adenocarcinoma of the Lung

Interventions

DRUG: AXL1717
DRUG: Docetaxel

Sponsor

Axelar AB